Innate Pharma Stock Forecast, Price & News

Innate Pharma (OTCMKTS:IPHYF) Frequently Asked Questions

Is Innate Pharma a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Innate Pharma stock.
View analyst ratings for Innate Pharma or view top-rated stocks.

How has Innate Pharma's stock been impacted by Coronavirus?

Innate Pharma's stock was trading at $7.1690 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IPHYF shares have decreased by 46.2% and is now trading at $3.86.
View which stocks have been most impacted by COVID-19.

Are investors shorting Innate Pharma?

Innate Pharma saw a increase in short interest in December. As of December 31st, there was short interest totaling 13,700 shares, an increase of 407.4% from the December 15th total of 2,700 shares. Based on an average trading volume of 2,700 shares, the short-interest ratio is currently 5.1 days.
View Innate Pharma's Short Interest.

Who are Innate Pharma's key executives?

Innate Pharma's management team includes the following people:

• Mondher Mahjoubi, Chairman-Executive Board & Chief Executive Officer
• Odile Belzunce, Senior VP-Compliance, IT & Operations
• Frederic Lombard, Chief Financial Officer
• Eric Vivier, Chief Scientific Officer & Senior Vice President
• Joyson Joseph Karakunnel, Chief Medical Officer & Executive Vice President

Who are some of Innate Pharma's key competitors?

Some companies that are related to Innate Pharma include C4 Therapeutics (CCCC), REGENXBIO (RGNX), Sorrento Therapeutics (SRNE), Replimune Group (REPL), Coherus BioSciences (CHRS), Immunocore (IMCR), Inhibrx (INBX), Vaxcyte (PCVX), Molecular Partners (MOLN), Sangamo Therapeutics (SGMO), SOPHiA Genetics (SOPH), Immunovant (IMVT), Adagio Therapeutics (ADGI), Century Therapeutics (IPSC) and Agenus (AGEN).
View all of IPHYF's competitors.

What is Innate Pharma's stock symbol?

Innate Pharma trades on the OTCMKTS under the ticker symbol "IPHYF."

How do I buy shares of Innate Pharma?

Shares of IPHYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Innate Pharma's stock price today?

One share of IPHYF stock can currently be purchased for approximately $3.86.

How much money does Innate Pharma make?

Innate Pharma has a market capitalization of $303.16 million and generates $80.47 million in revenue each year.

How many employees does Innate Pharma have?

Innate Pharma employs 244 workers across the globe.

What is Innate Pharma's official website?

The official website for Innate Pharma is www.innate-pharma.com.

Where are Innate Pharma's headquarters?

Innate Pharma is headquartered at 117 AVENUE DE LUMINY - BP 30191, MARSEILLE I0, 13009.

How can I contact Innate Pharma?

Innate Pharma's mailing address is 117 AVENUE DE LUMINY - BP 30191, MARSEILLE I0, 13009. The company can be reached via phone at (343) 030-3030, via email at [email protected], or via fax at 33-04-30-30-30-00.